The point of no re­turn for Mer­ri­mack? Can­cer drug de­vel­op­er ax­es yet an­oth­er drug and more staff

Mer­ri­mack just can’t catch a break.

On Thurs­day, the com­pa­ny said it was aban­don­ing its ex­per­i­men­tal drug, MM-310, af­ter an ear­ly-stage study in­volv­ing pa­tients with sol­id tu­mors showed that treat­ment with the drug was cu­mu­la­tive­ly tox­ic to pa­tients, de­spite tri­al pro­to­col amend­ments.

As a re­sult, the com­pa­ny said it was cut­ting jobs, but did not spec­i­fy how many. It now has two pre­clin­i­cal drugs — MM-401 and MM-201 — left in its ar­se­nal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.